Federal Register / Vol. 69, No. 198 / Thursday, October 14, 2004 / Notices 61021

the Director, Management Analysis and 

Services Office, CDC, pursuant to Public Law 

92–463. 

Matters to be Discussed: The meeting will 

include the review, discussion, and 

evaluation of applications received in 

response to Request for Applications OH–04–

002. 

Contact Person for More Information: S. 

Price Connor, Ph.D., Research Grants 

Program Officer, Office of Extramural 

Programs, National Institute for Occupational 

Safety and Health, CDC, 1600 Clifton Road, 

NE., MS–E74, Atlanta, GA. 30333, Telephone 

404–498–2530. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry.

Dated: October 6, 2004. 

Alvin Hall, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention (CDC).

[FR Doc. 04–23022 Filed 10–13–04; 8:45 am] 

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel: Occupational Health 

and Safety Research, Program 

Announcement (PA) 04038 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting:

Name: Disease, Disability, and Injury 

Prevention and Control Special Emphasis 

Panel (SEP): Occupational Health and Safety 

Research, Program Announcement (PA) 

04038. 

Times and Dates: 2:30 p.m.–2:45 p.m., 

November 1, 2004 (open). 

2:45 p.m.–5:30 p.m., November 1, 2004 

(closed). 

Place: Office of Extramural Programs, 

Room 1419, Building 24, Executive Park 

Drive, Atlanta, GA 30333, Telephone: 888–

414–5419 Pass Code 18205 (this meeting will 

be held via teleconference). 

Status: Portions of the meeting will be 

closed to the public in accordance with 

provisions set forth in section 552b(c) (4) and 

(6), Title 5 U.S.C., and the determination of 

the Director, Management Analysis and 

Services Office, CDC, pursuant to Public Law 

92–463. 

Matters to be Discussed: The meeting will 

include the review, discussion, and 

evaluation of applications received in 

response to Program Announcement Number 

04038. 

Contact Person for More Information:

Pamela J. Wilkerson, Designated Federal 

Official, Office of Extramural Programs, 

National Institute for Occupational Safety 

and Health, CDC, 1600 Clifton Road, NE., 

MS–E74, Atlanta, GA. 30333, Telephone 

404–498–2530. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry.

Dated: October 6, 2004. 

Alvin Hall, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention.

[FR Doc. 04–23025 Filed 10–13–04; 8:45 am] 

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N–0437]

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request;Medical Devices; 

Third-Party Review Under the Food 

and Drug Administration 

Modernization Act, Third-Party 

Premarket Submission Review, and 

Quality System Inspections Under the 

United States/European Community 

Mutual Recognition Agreement

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal agencies are required to 

publish notice in the Federal Register

concerning each proposed collection of 

information, including each proposed 

extension of an existing information 

collection, and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

information collection requirements for 

medical devices; third-party review 

under the Food and Drug 

Administration Modernization Act 

(FDAMA), third-party premarket 

submission review, and quality system 

inspections under the United States/

European Community (U.S./E.C.) 

Mutual Recognition Agreement (MRA).

DATES: Submit written and electronic 

comments on the collection of 

information by December 13, 2004.

ADDRESSES: Submit electronic 

comments on the collection of 

information to: http://www.fda.gov/

dockets/ecomments. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document.

FOR FURTHER INFORMATION CONTACT:

Peggy Robbins, Office of Management 

Programs (HFA–250), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document.

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology.

Medical Devices; Third-Party Review 

Under FDAMA, Third-Party Premarket 

Submission Review, and Quality 

System Inspections Under U.S./E.C. 

Mutual Recognition Agreement (OMB 

Control Number 0910–0378)—Extension